Scottish Enterprise

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

Ilosta specializes in developing novel technology to reduce the cost, time, and dangers associated with monitoring the health of engineering structures and extending their lifespan without requiring human intervention.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Ibis Vision has developed ‘Ring of Sight’ (ROS), a unique eye test that is specifically designed for the early detection of glaucoma. Worldwide, glaucoma is the second most common cause of blindness and is caused by a build-up of pressure within the eye which in turn can damage the optic nerve and the nerve fibres from the retina. Once damage is detected, it is usually permanent and therefore it is vital to make the diagnosis as soon as possible to commence treatment. The ROS product is based on patented technology covering the use of visual field testing using a cursor and LED screen: the product is currently configured for use within a Windows environment and has two developed tests in play; the Full Threshold Test and the Suprathreshold Test. The ROS application will be hosted remotely and deployed via the latest in Cloud technology enabling users to access the application from wherever they are situated. All data is stored on secure encrypted servers to ensure data privacy and security is maintained at all times.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

PneumoWave is focused on developing innovative real-time monitoring solutions for patients with respiratory conditions, enabling them and their healthcare providers to track respiratory rates and performance outside of clinical settings. The company combines proprietary sensor technology with an AI-driven digital therapeutic software platform to enhance patient care. Its technology features advanced algorithms that accurately detect various respiratory adverse events, while a biosensor continuously collects and wirelessly transmits data for analysis. This system includes an alert mechanism that promptly notifies healthcare providers, facilitating early intervention and improving the overall management of respiratory health. By rationalizing medication use and identifying early signs of deterioration, PneumoWave aims to reduce hospital admissions and minimize the need for face-to-face appointments, thereby transforming respiratory care.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

WellFish Tech is an aquaculture company headquartered in Bridge of Weir, United Kingdom, focused on enhancing fish health monitoring through rapid and non-lethal blood analysis. Founded in 2021 by Brian Quinn, the company aims to improve the sustainability and productivity of the aquaculture industry. WellFish Tech provides health monitoring services that assess fish stock in marine net pens, including smoltification, toxicity assessment, and aquafeed optimization. Their dynamic diagnostic platform is designed to adapt to the evolving needs of the growing aquaculture sector, enabling industrialists to reduce costs, increase productivity, and ultimately enhance profitability.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring patient feedback on medications. Its primary offering, the Medsmart application, collects insights on how and why patients take their medications. The company utilizes advanced artificial intelligence and natural language processing to analyze unstructured social feedback, providing pharmaceutical companies with deep insights into patient experiences. Through its PatientMetRx® platform, Talking Medicines enables clients to make data-driven marketing decisions by delivering comprehensive patient insights that enhance advertising effectiveness and improve health outcomes. Additionally, the company offers various services, including real-world persona data reports, digital focus group solutions, and custom analytics tailored to specific medicines. Founded in 2013 and rebranded from Virtual Genie Limited in 2015, Talking Medicines serves the pharmaceutical and healthcare sectors, aiming to revolutionize the industry by providing unprecedented access to patient voices.

PneumoWave is focused on developing innovative real-time monitoring solutions for patients with respiratory conditions, enabling them and their healthcare providers to track respiratory rates and performance outside of clinical settings. The company combines proprietary sensor technology with an AI-driven digital therapeutic software platform to enhance patient care. Its technology features advanced algorithms that accurately detect various respiratory adverse events, while a biosensor continuously collects and wirelessly transmits data for analysis. This system includes an alert mechanism that promptly notifies healthcare providers, facilitating early intervention and improving the overall management of respiratory health. By rationalizing medication use and identifying early signs of deterioration, PneumoWave aims to reduce hospital admissions and minimize the need for face-to-face appointments, thereby transforming respiratory care.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.

Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

Aiber develops innovative software and medical support systems aimed at enhancing emergency care in challenging environments, such as in the air or at sea. Their solutions leverage Bluetooth sensors to enable wireless monitoring of vital signs, facilitating the identification of patient deterioration or improvement. By providing medical-grade sensors, Aiber empowers crews to manage medical emergencies with confidence and ensures that vital health information is shared with ground-based medical providers. This approach allows flight businesses to deliver consistent and effective care to passengers during flights, supporting international first response efforts on the frontline of emergency care.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring patient feedback on medications. Its primary offering, the Medsmart application, collects insights on how and why patients take their medications. The company utilizes advanced artificial intelligence and natural language processing to analyze unstructured social feedback, providing pharmaceutical companies with deep insights into patient experiences. Through its PatientMetRx® platform, Talking Medicines enables clients to make data-driven marketing decisions by delivering comprehensive patient insights that enhance advertising effectiveness and improve health outcomes. Additionally, the company offers various services, including real-world persona data reports, digital focus group solutions, and custom analytics tailored to specific medicines. Founded in 2013 and rebranded from Virtual Genie Limited in 2015, Talking Medicines serves the pharmaceutical and healthcare sectors, aiming to revolutionize the industry by providing unprecedented access to patient voices.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

Citruslabs is a provider of a clinical trials and healthcare technology platform that assists research organizations in patient recruitment and retention for clinical studies. The company operates a health-application network that offers users engaging content related to physical exercises, nutrition, and games. This platform educates users on the risks and benefits of participating in clinical trials, facilitating informed decision-making. By providing this valuable data to clients, Citruslabs enables healthcare organizations to efficiently identify and pre-screen qualified candidates for trials, thereby streamlining the recruitment process. With a commitment to supporting both small and large research initiatives, Citruslabs plays a vital role in enhancing the clinical research landscape.

i2eye diagnostics is a spin-out company from the University of Edinburgh and the Edinburgh BioQuarter.

DYSIS Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. The company has developed the DYSIS Colposcope, a digital device that assesses the aceto-whitening reaction and presents the findings in an intuitive map format. In addition to the colposcope, DYSIS Medical offers a range of accessories, including both disposable and reusable specula, diathermy loops, and coagulation balls, as well as software for image data management and development of the DYSISmap. Founded in 2002 and rebranded in 2011, DYSIS Medical aims to improve early detection of cancers, potentially addressing significant healthcare challenges globally. The company maintains sales offices in Tampa, Florida; Edinburgh; and Athens, Greece.

Viopti was established in May 2009 to bring to market a range of innovative premium branded products for the contact lens user. The companies lead product is the contactspod, a unique disposable contact lens case that is pre filled with solution and provides the end user with a hygienic option for storing their contact lenses. The company has licensed the right to use the Polaroid brand across a range of products including eye drops and solutions. Polaroid is an iconic brand recognised and trusted globally. Viopti has been supported technically by IT partners Ote for solutions and regularity control and Wideblue for product development. Contactspod is the world's first, pre-filled, single use contact lens case. Hermetically sealed containing sterile multi-purpose solution, it is perfect when travelling and is ideal for spa's, beauty treatments & active sports. Contactspod is small, compact, convenient to carry around and easy to use. These are significant benefits for the traveller especially when flying, given today's baggage weight restrictions.

Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby saving clinicians time and improving productivity in healthcare settings. Founded in 2010 and based in Edinburgh, the company offers products such as the Blackford Workflow Server, which integrates into hospital IT frameworks, and the Blackford Smart Localizer, designed for seamless comparison of imaging studies within existing systems. These tools enable users to conduct comparisons with a single click, typically resulting in time savings of 10% to 20%. Blackford’s technology employs advanced algorithms and multi-core processing to facilitate rapid registration of scans from various sources. The company partners with multiple imaging system providers and has expanded its reach by collaborating with organizations outside diagnostic imaging to enhance their offerings. Blackford Analysis has experienced significant growth, with sales offices in both the UK and the United States, and continues to develop bespoke image processing solutions to meet diverse healthcare needs.

Viopti was established in May 2009 to bring to market a range of innovative premium branded products for the contact lens user. The companies lead product is the contactspod, a unique disposable contact lens case that is pre filled with solution and provides the end user with a hygienic option for storing their contact lenses. The company has licensed the right to use the Polaroid brand across a range of products including eye drops and solutions. Polaroid is an iconic brand recognised and trusted globally. Viopti has been supported technically by IT partners Ote for solutions and regularity control and Wideblue for product development. Contactspod is the world's first, pre-filled, single use contact lens case. Hermetically sealed containing sterile multi-purpose solution, it is perfect when travelling and is ideal for spa's, beauty treatments & active sports. Contactspod is small, compact, convenient to carry around and easy to use. These are significant benefits for the traveller especially when flying, given today's baggage weight restrictions.

Touch Bionics Inc., is a Livingston, Scotland, UK-based developer of advanced upper-limb prosthetics.

Blackford Analysis Ltd. specializes in software solutions that enhance the comparison of medical images, thereby saving clinicians time and improving productivity in healthcare settings. Founded in 2010 and based in Edinburgh, the company offers products such as the Blackford Workflow Server, which integrates into hospital IT frameworks, and the Blackford Smart Localizer, designed for seamless comparison of imaging studies within existing systems. These tools enable users to conduct comparisons with a single click, typically resulting in time savings of 10% to 20%. Blackford’s technology employs advanced algorithms and multi-core processing to facilitate rapid registration of scans from various sources. The company partners with multiple imaging system providers and has expanded its reach by collaborating with organizations outside diagnostic imaging to enhance their offerings. Blackford Analysis has experienced significant growth, with sales offices in both the UK and the United States, and continues to develop bespoke image processing solutions to meet diverse healthcare needs.

Actual Analytics Limited specializes in behavior analysis solutions for scientific research, focusing on the automatic monitoring of laboratory animals. The company offers products such as ActualTrack, which tracks the movement of various species like rodents and zebrafish via video analysis, and Actual Home Cage Analysis (ActualHCA), which facilitates non-invasive data collection and automated behavioral analysis of group-housed rodents. By utilizing advanced video analysis technology, Actual Analytics enables researchers to streamline the drug discovery process, particularly for treatments related to Central Nervous System diseases such as Alzheimer’s and Parkinson’s. This automation not only enhances accuracy but also reduces costs associated with traditional manual tracking methods. Founded in 2009 and headquartered in Edinburgh, UK, Actual Analytics distributes its tools in several countries, including the United States, Spain, Taiwan, China, and Germany.